Upcoming Earnings: Q2 '26
Estimated EPS
-$0.14
Estimated Rev
$0M
$ALT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.18 up 30.77% YoY • Altimmune expects to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026. Topline data from the RECLAIM Phase 2 AUD trial is expected in the third quarter 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.14 | -- | -- | N/A |
Q1 '26 | -$0.24 | -$0.18 | 25.71% | BEAT |
Q4 '25 | -$0.23 | -$0.27 | -15.38% | MISSED |
Q3 '25 | -$0.27 | -$0.21 | 22.83% | BEAT |
Q2 '25 | -$0.34 | -$0.27 | 19.70% | BEAT |

/filters:format(webp)https://news.stocktwits-cdn.com/large_Getty_Images_2225995334_jpg_67de820c56.webp)


